Q-omics provides the consensus-scored MIR670HG profile across patient tissues and cancer cell-line models. MIR670HG expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR670HG is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR670HG RNA expression shows 7,716 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KIRC, and TGCT as cancer lineages where MIR670HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR670HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR670HG survival associations across molecular data types. MIR670HG RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR670HG RNA expression–survival associations across cancer types. High MIR670HG expression shows unfavorable associations in CESC, BLCA, UVM, COAD and THCA, but favorable associations in PAAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR670HG RNA expression.
This table summarizes MIR670HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR670HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR670HG shows lower tumor expression in KIRC, THCA, UCEC, KIRP, KICH and STAD. The KIRC box plot shows higher MIR670HG RNA expression in normal versus tumor tissue (log2 FC = −0.096, t-test p < 0.001).
This table shows molecular features associated with MIR670HG in patient tissues and cancer cell lines. In patient samples, MIR670HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
